SNAP GmbH is the Startup of the Week 43: Moving people

Health & FoodTech, IT & ICT

You canControlling technical systems with the help of thoughts – for many people this still sounds like science fiction. But it is already reality. Our Startup of the Week SNAP GmbH develops products and services in exactly this area: the interface between the human brain and technical systems. Sinah Grube from SNAP GmbH explained to us in an interview how exactly this works and what SNAP GmbH contributes to the development.

Hello Sinah! Thank you for taking the time for us today. Please explain what SNAP GmbH does.

We at SNAP GmbH, based in the BioMedicineCentre in Bochum, concentrate on the development of products and services in the following areas brain-computer interface (BCI systems), artificial intelligence (AI systems), data hosting, technical assistance systems and motion analysis.

Your vision lies in the field of brain-computer interfaces. How does that work?

The BCI is an interface from the human brain to a technical system, such as a computer or a mobile phone. In electroencephalography (EEG), we place electrodes on the scalp to record the activities of the brain. The neurological data obtained can be used to control technical systems in the environment through the pure thoughts of the human being. The possible applications are immense and offer great potential for the future (e.g. from the entertainment industry to health care). We are currently also part of two funded projects in this area, VAFES and ReXo, which are supported by the State of NRW and the European Union.

At ReXo project workers develop a biomechanically designed, adaptive exoskeleton for the upper extremities. In that project SNAP enables control of the rexoskeleton via the brain. Our goal is the training of a very well-functioning AI solution for a BCI. So SNAP GmbH decided right from the start to evaluate kinematic data for various fields of application. Thus we are not only AI specialists in the field of neurological data, but also in the evaluation of kinematic data. One example of an AI solution is our AI-based motion detection system, which we call AnaKin (analytical kinetics).

For motion analysis, we have developed our own in-house sensors that are attached to the body for data acquisition. The AnaKin records the movements of the wearer and memorises certain movements. Of course, it is also possible to purchase our own portable sensors, so that the movement data can be individually trained with the AnaKin. The trained AI can recognise whether, for example, a person carries out a movement correctly or not. On customer request SNAP GmbH as a service provider also offers pattern recognition and motion analysis on AI basis of already existing data sets recorded with external sensors. In addition to movement tracking, there is also the possibility of pure gesture control with our sensors. Only with a wristband equipped with our described sensors, gesture control becomes reality. With this, smartphones, games, tablets, drones can be controlled by a single wipe with the hand in the air.  

This is really an exciting field. What makes you stand out from your competitors?

In fact, there are very few companies in Germany that develop BCI systems, so we as a company are already extremely interesting for external partners and investors. In addition, we record and analyse neurological data synchronously with kinematic data. This combination is also not always common. 

Our motion analysis with our self-developed sensors offers the user considerable added value, asan inertial sensor transmitted the data wirelessly. Consequently, mobile use is also possible outside a laboratory. You can easily attache the sensor to the body with straps. An app collects and analyses the data. Furthermore, a USP in motion analysis is the connection to our individual AI solution. With regard to our digital assistance system, it can be said that we have the special feature here that our therapy platform is used in telemedical care. For example, doctors and physiotherapists can view the course of movement and training data. 

The trend towards video consultation hours will also increase more and more due to the current Covid-19 situation. Digital and AI-based assistance systems will provide an optimal basis for this. A very noteworthy point is, of course, that all neurological as well as kinematic data will be stored in Bochum and processed in compliance with DSGVO.

In addition to our products and services, the people behind the scenes at SNAP are unique. We are an intercultural, young, dynamic team that works every day with a great technical passion to invent technology that enhances our capabilities, our community and our world.

How do you integrate your solutions into a successful business model?

In the field of brain-computer interfaces we receive many interesting and individual enquiries for the development of new business fields. In the case of specific enquiries, we work together within the framework of development contracts. Furthermore, we are currently being supported in the BCI area by the state of North Rhine-Westphalia and the European Union within the framework of two funding projects, VAFES and REXO.

Our business model for processing kinematic data is similar to our BCI. The customer can choose between two options within the first meeting: 

  • The customer buys SNAPs specially developed sensors, which they need for data acquisition of the movements. Subsequently, an AI solution for the motion data is trained with our sensors in a customised service. 
  • The customer does not need any sensors, as data records from external sensors are already available. Therefore, we only train an AI for the existing motion data with the AnaKin individually according to customer requirements. 

We market our digital assistance system, the IRhythmic, as a training device and can be purchased from us on the market including a corresponding app. 

As our focus is on the health industry, we also offer a prevention course from SNAP GmbH for fall and movement prevention. The statutory health insurance companies usually pay for almost the complete prevention course.

An important note to all investors: We are always on the lookout for further investors, as venture capital can greatly accelerate the development of the BCI for the consumer market.

You just mentioned that you focus on the health industry. Are these the only potential clients you are addressing?

We address a very large target group with our products and services. Our focus is on the entire healthcare sector as well as the games industry. In the healthcare sector we can offer a grandiose added value in the area of prevention as well as rehabilitation. In the games industry, on the other hand, we can offer interactions with computer games, for example. We are currently gaining a foothold in the German market. For the future we cannot and do not want to exclude international marketing.

What stage of development are you currently in? And where do you want to go?

Very good question – because there is actually something from every development phase in our company. Our vision is and remains that we will develop a robust, intuitively operable BCI system that recognises and implements commands from the brain – a kind of “Siri” for thoughts. Due to our unique selling points, we have already received several requests for such a BCI system. So far, we can only process relatively simple commands with the BCI and are still bound to the computer. We want to become more precise so that, for example, a paraplegic person can move his hand – or legs – as naturally as possible with the help of an exoskeleton.

The next step is to transfer the AI (for neurological data) to portable devices. On the other hand, we have already successfully launched our sensors for motion analysis with the motion recognition system AnaKin. The same applies to our digital assistance system – the IRhythmic. Here we are in good contact with health insurance companies. End customers, such as hospitals and physiotherapists already use the training device. Our certified prevention course is also already successfully conducted online. Our sponsored projects, ReXo and VAFES, got off to a good start at the beginning of the year and we are on schedule here with our cooperation partners and are thus keeping on course.


Sinah, thank you very much for the exciting interview. We will definitely continue to follow SNAP’s developments and wish you continued success!

If you would like to learn more about SNAP GmbH, please visit their Innoloft profile.

Healex is the Startup of the Week 42: Connecting clinical research and clinical care

Health & FoodTech, IT & ICT

Currently, the medical sector has a major information management problem. This has been caused by the increase in knowledge in its scope, but also in the level of detail. The consequences are delays in the transfer of research results to effective therapies and massive cost increases due to increased expenditure. The medical sector definitely needs a solution. Our Startup of the Week, Healex, has developed an exciting platform approach that can help many stakeholders in the healthcare sector. We met Christoph Plamper from Healex for an interview.

Hello Christoph! Thank you for taking time for us today. Please explain shortly what Healex is.

Healex is a software and consulting company based in Cologne and Berlin that develops products and solutions for the efficient planning, control and acceleration of clinical trials, for therapy consulting in patient care and for the management of large volumes of clinical and health data.

You have developed your own platform for this, right? What is the goal of the platform?

Yes, exactly. The “Healex Site Management System” (SMS) brings together sponsors, researchers and investigators on an innovative platform and enables the planning, implementation and collaboration in clinical studies across multiple sites. Clinical studies are thus significantly accelerated and digitally managed. By supporting international medical data standards such as “FHIR” and the “Healex Clinical Hub”, a FHIR-based platform for structured clinical data, the “Healex Site Management System” (SMS) and our other solutions can be seamlessly integrated into existing hospital systems and research infrastructures, enabling the easy integration and use of structured clinical data for research and care.

What is special about this approach?

We bring together sponsors from pharma, clinics, research networks, researchers and investigators on our platforms. With the platforms we provide powerful collaboration tools and solutions for structuring clinical data. Both ensure that personalised therapies can be developed faster. In addition they are more data-driven and thus more cost-effectively in the long term.

Do you only sell your Healex Site Management System?

No. We develop and sell IT solutions in the B2B healthcare market, mainly our own but also partner solutions. This happens usually through multi-year license agreements, both SaaS and on-premise. We focus on platform models as well as product families and individual products. Roughly, we have divided our product and business model into two levels: Our core products are primarily aimed at large hospitals, pharmaceuticals and research organizations and are networked infrastructure solutions. Our Corona web tools are flexible web solutions that many industries can use. The core of our business model is that you can use almost all our solutions independently but also connect them and use them together. Business model is 70% product sales and development and approx. 30% consulting. We do not offer any other services apart from our core products.

Who falls within your target group?

Our target groups are mainly large university hospitals and research networks. Many hospitals, pharmaceutical companies and health insurance companies are customers as well.

What are your successes that you like to look back on?

For more than twelve years we have been supporting research groups and physicians in the integration of clinical care and research. Due to our close cooperation with one of the largest university hospitals in Germany, we have deep experience and proven solutions to critical processes and problems in clinical research and care. For many of these challenges, we have already delivered solutions that thousands of researchers and physicians use every day in numerous multinational clinical trials.


Christoph, that brings us to the end of our interview. Thank you very much for the exciting interview! We wish you continued success and will definitely continue to follow your developments.

If you want to learn more about Healex, you can take a look at the corresponding Innoloft profile.

The Business Development Agency of the City of Aachen and Innoloft launch digital innovation platform for EUREGIO Meuse-Rhine

Banking & Finance, Energy & Environment, Health & FoodTech, IT & ICT, Mobility

Digital platform supports Aachen’s companies and startups

With its digital innovation platform (DIP), the Business Development Agency of the City of Aachen supports companies and start-ups: The platform offers the possibility to get new business partners (for example B2B customers). In addition, the innovation platform presents innovative technologies and solutions from the region and thus supports companies in innovation scouting.

Platform solution for business activities

The DIP is available free of charge to all companies in the Aachen region. Thus, numerous features of the platform enable the initiation of business relations between companies and the direct exchange among each other. For this purpose, companies, research institutions and start-ups can register on the platform and enter their own profile. This profile can then be used to post products, services and technologies to communicate them in Aachen and beyond. To enable solution providers and solution seekers to find each other directly on the platform, it is possible to publish customer and cooperation requests in the form of “Requests” on the platform. A matchmaking algorithm helps to find suitable partners and customers automatically.

Contact initiation and networking by digital means

Users have the possibility to get in contact with each other via the built-in chat functions. This facilitates the exchange in times of home office without the opportunity for personal meetings. “The DIP platform can thus take on a sub-task of trade fairs, events and conferences, namely getting to know, networking and initiating business and innovative projects,” says Dieter Begass, Head of Economic Development Aachen. It allows us to overcome spatial distances, because it enables us to exchange with business partners independent of time and location. After Corona, the DIP will continue to be operated for registered users and can provide valuable support to companies, research institutes and start-ups in initiating cooperation and finding innovative solutions.

It is precisely with this in mind that the HYPEREGIO DIP was initiated by the Department of Economics, Science and Europe of the City of Aachen and other players such as AGIT within the framework of the Interregio programme “Hyperegio EarlyTech” and implemented together with Innoloft GmbH. The official launch of the platform will take place on September 7. Interested parties are asked to register for the digital launch event at From September 7th, a free registration will be available under the link


About the DIP Platform

The objective of the “Early Tech Program” is to network innovations from companies and research institutes in the Euregio. Economic added value can be generated by creating synergies and accelerating the market launch of technologies. A large part of the activities for networking and creating transparency in the area of innovation will be bundled digitally. The digital innovation platform (DIP) serves this purpose. It is docked to the constantly growing digital innovation network of Innoloft GmbH and to the Hyperegio platform as user interface. With their presentation on the platform, startups, research institutions and companies can draw attention to projects and their own products, network with each other and enter into new collaborations. In the search for competencies and innovative customer solutions, DIP helps with innovation scouting.

About Innoloft GmbH

The Innoloft network promotes innovation by connecting the most innovative players from all technology sectors. The network is designed to break down barriers between companies, investors and start-ups worldwide and open up economic opportunities for them. To this end, specific digital formats are used to identify development partners, new technologies, investment cases or customers and to bring together corresponding players on the B2B platform. Users are thus supported in partner acquisition, innovation scouting and lead generation.

Startups of the Month – June 2020

Energy & Environment, Health & FoodTech, IT & ICT, Mobility

Our five startups of the week of june at a glance

In June, the startups OMNIA, Genie Enterprise, Famedly, Vimbee and Synertics gave us exciting insights into their solutions and innovations with their Startup of the Week interviews. We have briefly compiled statements about their business models, markets, target groups and solution approaches for you here, in our startups of the month format. You can read the details in the individual interviews. Moreover, you can contact them directly via our messenger function in our network. Here you can also present yourself with your own profile and get in contact with the startups.  

OMNIA – Leading transformation processes to success (CW23)

We follow a very simple approach in what we do: ‘master, quantify, implement’.“ – Andreas Pointvogl, Managing Partner at OMNIA 

The energy turnaround is still in full swing. More and more companies and energy suppliers are converting their entire systems. However, this will cost time, money and probably also a lot of nerves. This is why OMNIA is focusing on precisely these transformation processes. Their expertise lays not only in the theory, but also in the actual implementation. OMNIA advises and accompanies their partners through every step of the process and the consultants become part of the team. This results in a mix of technical experts, development workers and politicians, which is unique in the market.

Customers include governments, international organisations, banks, public and private companies that are in a transition process, want to accompany it or initiate it. The current focus is on the energy sector, with OMNIA also developing new services in the field of sustainable financing. You can read more details about them and their services in the interview or find out more in their requests.

Read the full interview with OMNIA

Genie Enterprise – Using artificial intelligence (CW24)

„We digitize human perception by using the latest research findings to create practical, sustainable solutions.” – Regina Keßler, founder of Genie Enterprise

Genie Enterprise develops products and applications using artificial intelligence and machine learning. In addition, they support their customers with their expertise through classic consulting. With their products they solve concrete problems in a specific area. One of the applications is WineGenie, a digital sommelier that suggests suitable wines to customers in the online shop, but also on site. The startup also offers solutions for the customer service area, which they can adapt according to customer needs. Human behaviour and perception are always the important basis on which to build. Currently, WineGenie is about to enter the market. At the moment they develop and test further solutions.

With large medium-sized and large companies as a target group, Genie Enterprise is dedicated to a variety of projects to make life easier for people with the help of AI. For more information, contact details and partnership requests, please refer to our database in your requests.   

Read the full interview with Genie Enterprise

Famedly – Successful communication in the health sector (CW25)

„Good medicine is created through good communication and teamwork, therefore Famedly bundles all communication channels and ensures that the right information reaches the right people.“ – Dr. Phillipp Kurtz, CEO of Famedly

New health data is generated every second. Therefore, to ensure optimal patient care, you must exchange the data securely and efficiently. Otherwise, errors in treatment or diagnosis can occur. Famedly has developed a solution for that. Famedly is a decentralized platform for medical cooperation. It enables a large number of medical institutions, such as hospitals and doctors’ practices, but also pharmacies and inpatient care, to improve cooperation within and outside the institution. Depending on the needs, there are different functions that can be used.

All functions meet the requirements of data protection and are absolutely safe to use and forward data. The open source technologies used by Famedly offer such a high level of data security that  also the French government and the German Bundeswehr use them. With Famedly, security and data protection no longer slows down digital progress in medicine, but provides the decentralized platform for smooth digital change. To contact Famedly directly, you can use our database and its requests.

Read the full interview with Famedly

Vimbee – Platform for consumers and companies (CW26)

Vimbee can become the world’s first and only prosumer network that turns consumers into valuable prosumers for businesses.” – Ehsan Shirangi, CEO of Vimbee

Vimbee is developing a platform for the exchange between customers and companies. On this platform, consumers can provide product-related feedback. This way, companies receive direct feedback on the success of their product. This knowledge about the consumer can also be used for market research purposes. The global economic system is mapped in digital form, which promotes real data mining innovation, growth and knowledge on a global level. The user generated content provides the opportunity to conduct recommendation marketing. For consumers, the use of the platform is free of charge, while companies have to pay for access. Here Vimbee offers different price levels. Currently, Vimbee is at the end of its testing and development phase. Take a look at the database to find out more about their request.

Read the full interview with Vimbee

Synertics – Data Driven Mobility Solutions (CW27)

“Compared to other solutions, which often only represent descriptive data, we offer solutions that specifically evaluate data, merge it with external databases and thus generate significant added value for the user by creating algorithms and applying AI methods.” – Manuel Pessanha, CEO at Synertics

The mobility industry faces many challenges: E-cars, sharing models and ensuring efficiency. One thing above all is needed for this – data. You must analyze and evaluate this data before it can be used. Synertics develops suitable applications for exactly this case. In other words: their platform solutions promote productivity and profitability of products and services in the mobility industry. That means that Synertics focuses on investors, operators and communities involved in charging infrastructure, car sharing and micro-mobility. They thus offer an analytical tool that provides valuable insights by evaluating data. Founded in early 2020, Synertics is now in the process of refining its technology. A beta version was already tested in 2019. Check them out on our platform.

Read the full interview with Synertics

Famedly is the Startup of the Week 25: decentralised platform for medical cooperation

Health & FoodTech

How can we develop good medical care? And can digitalisation really help? New health data is generated every second. To ensure optimal patient care, this data must be exchanged securely and efficiently. This week’s Startup of the Week is Famedly. With their decentralised platform, data exchange and collaboration is much faster. CEO Phillipp Kurtz told us more about Famedly in today’s interview.

Hello Phillipp! Thank you for taking the time today! Why don’t you briefly explain to our readers what Famedly is?

Sure! Famedly is a comprehensive medical collaboration platform delivered as a single, distributed application that is fundamentally changing the way healthcare professionals collaborate and share information.

How do you have to imagine that?

Famedly is both a product and a platform. It is a product in the sense that it is a single decentralized medical team collaboration application that can be bought and used. It is also a platform and a framework in which an unlimited number of additional medical use cases can be represented. Flexible interfaces and bots ensure this. Medical service providers have a fully functional, ready-to-use product right out of the box, but there are not restrictions in terms of expansion and integration with other systems.

With the chat-based application, medical care providers provide their employees with a classic, data protection-compliant messenger. The function of the messenger is supplemented by flexible role concepts and intersectoral, partially automated processes to form a collaboration solution. Via an administration panel we manage these extended functions. Famedly handles all processes and relevant events in real-time. The decentralized architecture and flexible, open interfaces enable the integration of locally available software and devices as well as digital health solutions available in the cloud. The result is a comprehensive care team collaboration platform.

That sounds like an exciting way to digitise the health sector! After all, many startups are entering the race with the goal of digitisation. What are you doing differently?

Famedly shortens processes through higher efficiency in all areas of medical care. For the first time, utilities can work together in a single platform. Good medicine is created through good communication and teamwork, so Famedly bundles all communication channels and ensures that the right information reaches the right people. Healthcare teams have complete visibility across the entire patient journey with a single trusted source of information, reducing the risk of avoidable errors and improving care.

In contrast to all other competitors, Famedly pursues a decentralized technological approach and thus offers absolute data sovereignty for each participating institution. The open source technologies we use offer such a high level of data security that also the French government and the German Bundeswehr make use of them. Famedly meets all security and data protection requirements and provides utilities with powerful functions that allow them to automate all processes. With the decentralised platform, security and data protection no longer slows down digital progress in medicine, but provides the platform for smooth digital change.

You said earlier that Famedly is a platform and a product at the same time. Does your business model reflect that?

Famedly offers its product (Care Team Collaboration Tool) as a Software-as-a-Service solution. In the classic freemium model, small institutions are free of charge, while the prices for larger institutions start at 19.90 € plus VAT in the introductory period. An on-premise installation is also possible. For this the effort must be evaluated individually. In addition to the core product, Famedly offers training for employees in the use of the software.

We negotiate access to the Care Team Collaboration Platform for digital health providers and IoMT solutions individually.

Your platform is aimed at the health sector. Did you narrow your target group down further?

No. We address all medical service providers with our product. These are nursing services and homes, doctors’ and therapists’ practices, pharmacies and above all hospitals. With our platform, we also address technology providers from the fields of digital health and Internet of Medical Things (IoMT) as well as health insurance companies and pharmaceutical companies.

The product itself, the Care Team Collaboration Tool, is located in the small market for Clinical Communications and Collaboration. This market has comprised approximately $549 million in 2017. The platform, however, connects products and services from the Internet of Medical Things market ($41 billion in 2017) and the digital health market ($95 billion in 2018). In this way, relevant long-term shares of these markets can be achieved.

At what stage of development are you right now?

We carried out a pilot project with a minimally functional product (MVP) last year until the beginning of this year. Now, the first customers are currently starting regular operation with the first stable version of our Care Team Collaboration Tool. It includes full messaging capabilities with full end-to-end encryption, role- and time-based routing of information, decentralized, intersectoral networking of healthcare providers, as well as task management and first process automation tools. In addition, discussions on larger projects with renowned clinics and care facilities are in the hot phase. We hope to make further announcements here in the near future.

Technically, the next major milestone is the connection to the primary systems (clinic information systems and practice management systems). Otherwise, the next big step is the conclusion of a first round of investments.

Phillipp, thank you very much for the super interesting interview! We wish you continued success with the development of Famedly and the investments.

Want to learn more about Famedly? Have a look at their Innoloft profile!

Digital B2B support to cushion the corona crisis

Energy & Environment, Health & FoodTech, Industry 4.0 & Logistics, Mobility, Smart City & Buildings

Innoloft supports you with its digital network in times of Corona

The COVID19 pandemic is spreading worldwide. It affects all of us and comes along with lots of uncertainty. What we will face in the upcoming months nobody knows. The economic consequences of the crisis can’t really be quantified yet. Nevertheless, we are not completely helpless facing the crisis. While there are major cuts in the analogue economy and the “lockdown” forces to slow economy activities, digital solutions can help to bridge this situation. Millions of people in Germany and around the world currently work from home. Doing home office would not work without internet connections, digital tools and platforms.

Plenty of companies are currently offering support in these times of crisis. We at Innoloft would also like to contribute and help to cushion the economic restrictions. We’re making our digital network platform available as a “white label application” to networks, associations, clusters, trade fairs and other private organizations. For this purpose we adapt it according to your corporate design. Our Innoloft network operating system is designed to initiate business contacts and connect solution providers, such as startups, with solution seekers.


What features does our digital B2B networking platform provide you?

– Create company profiles & personal profiles

– Place technologies, products and services

– Find business partners

– Automated business matchmaking

– Share news across your ecosystem

– Access a global network of innovation stakeholders


In addition to these key functions, the digital B2B network platform with its network feed, chat and mailing functions between network members offers further opportunities to exchange information and stay in touch with network users. Thus, the platform supports you in establishing new business relationships and serving existing ones, regardless of time and place.


Economic added value via digitised business relations also for the time after COVID19

With our digital B2B network platform, we would like to give you support for a difficult period of time. For this reason our offer is limited in time. For a period of six month, we are able to provide you with the platform in your design and we’ll make ends meet to shift the development costs. The platform is only suitable as a business network and is not designed for private use.

In the long term, we want to be available to you as a digital B2B network that will enable you to prepare for the digital future, even after the coronavirus. Our platform offers you and your network members the chance to network effectively with other companies, start-ups, organisations. You can establish and maintain business relationships in a digital manner. With the functions mentioned above, our platform offers numerous opportunities for new “customer leads”, partnerships, contacts, innovations and projects.


Learn more about our Platform

Are you interested in our six-month Corona B2B support offer and would like to learn more about it?
Get in touch with our CEO, Sven Pietsch.

Contact and further information

Phone: +49 152 33668237

Schedule an Appointment

inveox is the Startup of the Week 8: Rethinking Pathology

Health & FoodTech

One out of every two people will confront a cancer diagnosis at some point in their life. That’s why each and every cancer test needs to be quick, safe and reliable. To increase safety and reliability, we need an automated system for histopathology. This system comes from inveox, our startup of the week. Shelley Pascual, Communications Specialist at inveox, told us in an interview what exactly is behind it and how it works.

Hi Shelley! We are glad you could join us today. Inveox is all about reducing mistakes in cancer diagnosises. How do you optimize the process in that area?

inveox brings artificial intelligence and a large data potential to cancer diagnosis by automating the pre-analytical process and reducing errors. The errors can occur, for example, due to sample mix-ups or data loss. At the same time, patient safety and laboratory efficiency are improved.

How do your products help to automate the process?

Research shows that tissue samples (biopsies) in today’s laboratories can be confused, contaminated or lost with a probability of 1-15%. But our products – an intelligent sample container, an automation device and a digital data platform – are designed to work as one coherent unit to make sample entry in histopathology safer, more efficient and reliable.

Thanks to a QR code, our intelligent sample containers offer all patients safety by ensuring that mix-ups and contamination of tissue samples are a thing of the past. The container also has an intelligent filter that enables automatic mounting in biopsy cassettes. In this way, the sample always remains in one container and its unique ID facilitates data transfer, track & trace and process control.

A complementary product, the automation device, increases the throughput and quality of tissue samples by processing dozens of samples simultaneously and in a consistent, systematic manner. This allows the laboratory technician to focus on value-added tasks rather than repetitive data collection and repackaging. More importantly, it introduces artificial intelligence and collects data on every single tissue sample. Until now, the data has either not been recorded or is stored away in paper and cardboard boxes instead of being aggregated for scientific research.

Finally, our digital platform opens the door to a new and truly connected laboratory of the future. It enables seamless communication between the doctor taking the biopsy, the lab technician, the pathologist, our container and our machines. In short, this platform enables us to integrate the entire diagnostic experience from the taking of a tissue sample to the delivery of a diagnosis.

Cancer affects people all over the world. Reducing the potential mistake rate is a major goal. Why is your approach better than others? What makes your idea stand out?

Not only is there an enormous demand for our innovation worldwide, but there is no direct competition for inveox, apart from the manual process of preparing biopsy samples in pathology laboratories. This pen-and-paper method, which has been performed by laboratory technicians for decades, misses the potential for data collection and utilization. It also requires technicians to remain alert and focused on monotonous tasks that can be performed by machines.

inveox solves the biggest single problem in histopathology by introducing the world’s first automated system for sample entry in histopathology, for which we hold the corresponding industrial property rights. We are the first to use a combination of hardware and software, but most importantly, we have designed it for the future so that it can collect and exchange data that can be used for medical research and further process optimization. We are the first in the market and have a solid base of investors and customers who believe in our cause and the value of our solution.

What business model do you use?

Our component-based product and a modular contract structure enable us to offer all laboratories (regardless of size and throughput) service packages tailored to their individual needs, while remaining flexible and scalable at all times. These consist of Hardware as Service, Software as a Service and consumables in various package sizes.

Since your product is intended for histopathology, the corresponding laboratories are probably your main target group, right? In how many countries do you already sell your product?

Exactly! Our customers are private and public histopathology laboratories, which may include residences, parts of hospitals, laboratory chains or research institutes. Currently we are mainly active in the DACH region with the aim of expanding into other EU countries.

The European market alone consists of 6,500 laboratories that process 1 billion tissue samples every year, which results in an addressable market of 2 billion euros per year. We are also aiming for a US market, which includes 9,000 laboratories that process 2 billion samples per year, resulting in a total addressable market of €4 billion per year, and finally a global market with a potential of more than €13 billion per year.

How advanced is your product? Is it already being used successfully?

Yes, considering that our company was founded almost three years ago, the current state of our product development can be considered quite advanced. Since then, our products have been used successfully and with high satisfaction by well-known customers. In August 2019, we closed a financing round of 17 million Euros, bringing our total financing to 23 million Euros, which will allow us to further expand our team, scale globally and enhance our software. We currently have a team of almost 100 teammates, consisting of approximately 30 nationalities, spread across our offices in Munich and Krakow.

Shelley, thank you for this super exciting insight into the world of inveox! We wish you continued success and are curious to see where you will develop into. If anyone wants to learn more about inveox, check out the requests on inveox’ Innoloft profile.

MagnoTherm Solutions is the Startup of the Week 6: Next generation cooling

Energy Efficiency and Environment, Health & FoodTech

Conventional cooling systems often use problematic gases. In this case “problematic” means extremely flammable, toxic or refers to a high greenhouse effect. Our startup of the week does without these gases in their products and uses magnetic materials instead. Timur Sirman, Co-Founder of MagnoTherm Solutions, explains today how this works exactly.

Hello Timur! Thanks for being here today. Our first question is this: What is behind MagnoTherm Solutions?

We develop and build environmentally friendly cooling units for the cooling and heating systems of the future: with magnetic materials without any problematic gases.

How does this process work?

Active metals are cyclically heated and cooled by means of a permanent magnet. This is done by the magnetocaloric effect of these active metals. They become warm when they are exposed to a magnetic field – and cold when the magnetic field is reduced. Using a water-based exchange medium, the heat and cold can be transported from the solid and made useful. For this purpose, motor, pump, valves and control elements are used.

Why is it better to dispense with gases and use magnetic materials instead?

Without the use of F-gases, flammable gases, toxic gases or other problematic gases, our system is up to 40% more efficient than the best compressor-based cooling system available today. And this is independent of the temperature stroke or temperature range. This can be achieved by individualizing the active metals. As a result, highly efficient systems can be realized even for warm ambient temperatures and small temperature strokes, with a greenhouse potential of zero.

And that in turn is better for the environment. How do you integrate it all into a business model?

Our cooling units are integrated by our customer into his cooling system and then sold to the user. Here we develop customized products for our integration partner. In doing so, we can respond very quickly and precisely to the respective needs of the user, as our standardized structure allows the active metals to be adapted to the requirements at any time.

Who do you address with your products?

In principle, we can implement cooling units with a cooling capacity between 100 W and 100 kW. The European supermarket refrigeration industry is the first sales market, as the challenges are the greatest there. However, other markets we address are IT cooling, industrial cooling and heat pumps.

What stage of development are you currently in? How mature is your product?

We are currently building the first prototype, which will have a cooling capacity of 500 W to 1kW. This year we will equip a cooling system for Food&Beverages with this. At the same time, we are in talks with development partners to build further systems.

Timur, I’m afraid we’ve come to the end of the interview. We thank you for the exciting interview and wish you continued success. To find more about MagnoTherm Solutions, you can take a look at their Innoloft profile!

Climedo Health is the Startup of the Week 3: Accelerating Clinical Research

Health & FoodTech, IT & ICT

Innovation in the health sector has many faces. To accelerate medical innovation, it is necessary to collaborate between different partners like Pharma companies, hospitals and patients. Climedo, our startup of the week offers a smart digital assistant that supports various stakeholders in the efficient and safe execution of studies, e.g. regarding new cancer treatments. We spoke to Catherine Higginson, Marketing Manager at Climedo Health, to find out more about their innovative idea.

Hey Catherine, thank you for taking the time today! Let’s dive straight into this interview. How would you pitch Climedo in one sentence?

Thank you for having me! Climedo’s mission is to bring the best treatment to every patient by empowering healthcare professionals with intelligent software solutions.

That is quite a big mission! What does that software solution look like in detail?

Climedo is a cloud-based platform consisting of three core elements: two integrated databases (a digital patient file, as well as a biodatabase) and the main module, which enables the execution of a large number of studies. It is available for laptop/PC as well as on a tablet or smartphone. This allows sponsors, physicians and medical professionals to access all relevant study data in a central, holistic solution, yet still tailored to their individual needs. The intuitive and flexible study design allows for cost-efficient execution of mono- and multi-center studies. Parameters can be validated and analyzed in real time. We use technologies that are particularly suitable for the processing of unstructured data – which we believe is a must-have in the healthcare sector. This data becomes available in an intuitive and comfortable user interface, so that even complex relationships can be displayed quickly and comprehensively. In order to guarantee the highest level of data and information security, our servers are located exclusively in Germany and are certified according to relevant industry standards.

What added value do your products generate that other existing solutions do not have?

Clinical trials usually involve several parties located at different sites (e.g. industrial partners, CROs, hospitals, patients, etc.). Parties tend to work with completely disconnected systems. In addition to that over 50% of all clinical studies are still conducted on paper or using spreadsheets. In light of the healthcare sector’s digital transformation and several new EU regulations awaiting us, this is no longer a realistic or sustainable solution. Bringing all data and results together costs a lot of time and money, which could instead flow into patient treatment. This is where Climedo comes in. We seamlessly connect all parties within a cloud-based system and enable the structured collection and management of all study-related data. Patients can also enter information, such as the efficacy of a drug or the satisfaction with an inserted implant, without any special IT knowledge via email or SMS. That means they do not need to visit study sites as often, saving both them and the physicians valuable time. Unlike existing solutions, Climedo is 100% user-oriented and connects all parties in a holistic system.

Especially the integration of patients sounds really helpful and time-saving! Do you offer your software as a service?

Yes, exactly! We have a SaaS model. It consists of a one-time set-up fee and a flexible monthly usage fee, depending on the scope of the study and the product portfolio.

Who do you address with Climedo Health? And which countries are you targeting?

Our target customers are medical device manufacturers, pharma companies, contract research organizations (CROs) as well as hospitals and academia. Currently, we are mostly active in the DACH region and in the coming year we would like to expand into additional EU countries. Furthermore, some of our Germany-based studies are already rolling out internationally, including in the USA.

So you are already established on the market and now in the process of expanding your start-up?

Yes! Our product is available on an international level and several industry and academic partners already use it. We recently secured a 7-digit finance round which will enable us to further grow our team, expand internationally and continue driving our software development to make clinical validation more efficient for our clients.

That sounds very exciting! Catherine, thank you for this interview! We hope to hear a lot more from you and wish you continued success! Those who are interested in your products or a cooperation with, can have a look at your Innoloft profile and your request for further information.

Flawless Communication in Healthcare

Health & FoodTech

Bureaucracy and inefficient communication channels tend to overwhelm large parts of the healthcare workforce. This creates unnecessary stress on staff and patients. As a result, there is an acute need to improve communication between all stakeholders in the healthcare system. In particular with regard to the content and the temporality of the transmitted information, e.g. patient data, there are still plenty of problems to be solved. In terms of content, this information can suffer from a lack of quality. In addition, the information does not flow fast enough so that it reaches decision makers in time, which in turn can contribute to flawed decision-making.

The following startups have recognized the communication problems in healthcare and invented intelligent, scalable solutions. This not only gives the patient better personalized care. Caregivers, doctors and other healthcare workers are relieved of repetitive, strenuous tasks. This saves valuable time that caregivers can spend with their patients instead of paperwork.

visidoo – Digitized Appointment Management

Failed appointments are frustrating and cause unnecessary stress. The organization around appointments including reminders costs time and money. visidoo has realized that these tasks can largely be automated using digital tools. The business model is a monthly lump sum for small practices and an amount per patient per month for larger practices. Communication between practice and patient takes place via the mobile visidoo app. It includes a messenger for practices, automatically sent out reminders and recalls. Patients benefit from a clear presentation of their appointments and upcoming check-ups, including for their children.


Patientus – Virtual Room instead of Waiting Room

Since April 2017, doctors and patients can be connected via video-conferencing thanks to internet-based communication software. Patientus service enables medical care from a distance and thus represents a complimentary offer. With their service, consultation and follow-up appointments can easily be carried out online. The need for physical contact between the doctor and patient is reduced, at least for aftercare. However, the attending physician may continue to make diagnoses only in an on-site interview with the patient. Patientus was acquired by jameda in early 2017.


eHealth Ventures – Synced Data between all Care Stakeholders

Nowadays, patient data is often shared slowly and on a request basis between care organizations. This leads to long wait times for patients and in the worst case, costly overdiagnosis and therapy. The Berlin-based startup eHealth Ventures GmbH offers POLAVIS CLINIC, a communication portal for hospitals, with which they can securely share relevant case data with resident physicians for follow-up. In addition, the software suite offers functionalities such as a mailbox and scheduling. The platform is connected to the hospital’s internal information system and retains the data on-site.


myo – A Holistic Elderly Care Communication Platform

Often, relatives and friends of people in need of care are curious and worried about their health. myos holistic care communication platform takes residents, relatives, carers and nursing home operators into account. It makes it easier for relatives to be in contact with residents and to be informed about their health. Caregivers gain time with the app by recording activities and preventing confrontational conversations. In an increasingly digitized healthcare environment, myo is a unique selling proposition for nursing home operators to attract more staff.


Examples from abroad

Healthcare systems are diverse across countries. Despite their common goal of returning patients to health, every system is unique. Each has its own regulations, culture, caregivers and patients. This is why every app and solution can’t just be copy-pasted from one system into another. Often, startups have to deal with plenty of bureaucratic hurdles. Nonetheless, below we present three international startups which improve communication within healthcare. They issue an outlook on what is already possible today.


KRY – Successful Telemedicine Model from Sweden

When KRY was founded in 2014 in Sweden, its founders wanted to ease the access to care and work on making waiting rooms a thing of the past. Via the KRY app, you receive care through a digital video doctor consultation, including diagnosis, prescriptions, sick leave and referral. KRY acts as a middle man and tries to get doctors, as well as patients to use their platform. Consultations and payments are handled inside the app, creating little bureaucratic effort. Despite not having an official launch date, KRY is about to be launched in Germany.


Komed Health – Real Time Hospital Communication Platform from Switzerland

An application with a similar structure to WhatsApp is Komed Health’s first software product. The startup wants to revolutionize the communication between all stakeholders inside of a hospital. Their application works synchronous and in real time across a range of mobile devices. It offers the possibility to create group chats specific to a single patient and bundle internal working groups to shorten communication channels. Currently the system is being used in multiple Swiss hospitals.


MUrgency – A Global Emergency Service from India

If you’re living in a developed country, chances are that you take the ability to summon an ambulance with your phone for granted. It is less known that millions of people do not have access to such systems. MUrgency’s vision is to use mobile web technologies to create a global emergency network and make this lifesaving tool accessible to everyone. MUrgency has an especially profound impact in regions with weak infrastructure, where its response times are quicker than comparable systems. 50.000.000 people have received care through MUrgency’s services. The app has integrated a feature that alerts MUrgency users of an emergency happening in their close proximity, to further reduce emergency response times.


Suki – Intelligent Voice Assistant for Doctors

The Redwood startup develops and sells Suki. It is a voice assistant that reduces the amount of time that needs to be spent on medical reporting. Doctors simply dictate their report and Suki transforms the speech into a format that is compatible with common hospital information systems. Suki claims that reporting with their software is up to 76% faster than traditional writing methods. The company has received over 20 million dollars in venture capital.